Selank — Wolverine Health

How it works

A Russian-developed anxiolytic heptapeptide, structurally related to tuftsin (an immunomodulatory tetrapeptide). The mechanism isn't clean: it appears to influence GABAergic transmission, BDNF expression, and enkephalin degradation. Russian clinical trials in the 1990s–2000s showed anxiolytic effects without sedation or dependence liability. Those trials were small and published in Russian-language journals — the Western evidence base is thin.

FDA status: No FDA approval. Not on the PCAC July 2026 review docket. Anticipated for PCAC second review in early 2027.
WADA status: Permitted in sport
Route: intranasal; subcutaneous injection

Key studies

Selank and its analogs: a review of biological activity — Semenova et al.

Selank is a synthetic analog of tuftsin with anxiolytic properties, reducing anxiety in experimental models without sedation, motor impairment, or withdrawal signs associated with benzodiazepines.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on Selank

Peptide bioavailability: why oral, subcutaneous, and nasal routes have different evidence bases

WADA

The route a peptide gets dosed by changes its evidence base more than most readers realise. Oral, subcutaneous, and intranasal each ask different questions of the molecule. Here is why the route a study used often does not match the route the product is sold under.

The HPA axis and cognitive peptides: how selank and semax may modulate stress response

WADA

The HPA axis is the body's stress-response chain — hypothalamus, pituitary, adrenal cortex, cortisol. Two Russian-tradition peptides get sold for stress and cognition. Neither sits where the marketing implies. Here is what each actually engages.

Selank: Russia's anxiolytic peptide and what the research actually says

WADA

Selank has been used in Russian psychiatric practice for over a decade as an anxiolytic with no sedation and no dependence. Here's what the comparative trials show, why the Russian evidence base is real but limited, and what Western replication would need to look like.

Selank vs Semax: two Soviet-era peptides, two cognitive angles

Selank and Semax get sold side-by-side as cognitive performance peptides. Neither was built for that. Here is what the actual evidence shows, where the Russian-literature replication gap sits, and how the July 2026 FDA review splits the two peptides apart.

Selank: Anxiolytic Nootropic Peptide Research and Regulatory Outlook

WADA

Science-journalism overview of Selank — a Russian-developed heptapeptide studied for anxiety reduction and cognitive effects, its evidence base, and why it sits outside both the July 2026 and February 2027 PCAC dockets.